Latin America News Network
SEE OTHER BRANDS

Following the news from Latin America

Latin America News Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America News Network.

Press releases published on September 4, 2025

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced …

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, …

Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025

Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025

Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by SKYLINE participants through month 36 and DAWN participants at 9 months or …

ORYZON Finalist at the 2025 European Lifestars Awards

ORYZON Finalist at the 2025 European Lifestars Awards

MADRID, Spain and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected …

Aventis Energy Announces VTEM Survey on the Sting Copper Project

Aventis Energy Announces VTEM Survey on the Sting Copper Project

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aventis Energy (“Aventis” or the “Company”) (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce that it has engaged Geotech Ltd. (“Geotech”) and completed a VTEM (Versatile Time-Domain …

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D

AZURE-2 evaluates the efficacy and safety of brelovitug as a monotherapy compared head-to-head with Hepcludex (bulevirtide) Enrollment in AZURE-1, a global pivotal clinical trial evaluating the efficacy and safety of brelovitug compared to delayed …

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today …

Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression. End of study, 40-week …

Robex Announces Amendments to Sprott Facility Agreement

Robex Announces Amendments to Sprott Facility Agreement

QUEBEC CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to provide an update on its US$130 million senior …

Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project

Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: …

Aeries Technology Announces Major Expansion Plans in India and Mexico, Adding 500 New Roles to Support Global Growth

Aeries Technology Announces Major Expansion Plans in India and Mexico, Adding 500 New Roles to Support Global Growth

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today announced ambitious growth plans to expand its talent footprint …

FEMSA to control 100% of OXXO Brazil

FEMSA to control 100% of OXXO Brazil

MONTERREY, Mexico, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) today announced it has entered into definitive agreements with Raízen, S.A. (“Raízen”) to …

FEMSA controlará el 100% de OXXO Brasil

FEMSA controlará el 100% de OXXO Brasil

MONTERREY, México, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” o la “Compañía”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) anunció hoy que ha llegado a un acuerdo definitivo con Raízen, S.A. ("Raízen") para terminar …

dLocal Announces Pricing of Secondary Offering

dLocal Announces Pricing of Secondary Offering

MONTEVIDEO, Uruguay, Sept. 04, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”), (NASDAQ:DLO) a technology-first payments platform, today announced the pricing of a previously announced secondary offering of 15,000,000 Class A common shares by an entity …

American Tungsten Progresses its IMA Mine Rehabilitation

American Tungsten Progresses its IMA Mine Rehabilitation

Vancouver, BC, Sept. 04, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) American Tungsten is pleased to provide an operational update, as it advances its vision to capitalize on …

Dynacor Provides Corporate Update Including Expansion Progress

Dynacor Provides Corporate Update Including Expansion Progress

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation") is pleased to provide a corporate update covering operations and progress on its expansion plan within West Africa and Latin America. Operational …

Robex Announces Voting Results for 2025 Annual General and Special Meeting of Shareholders

Robex Announces Voting Results for 2025 Annual General and Special Meeting of Shareholders

QUEBEC CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to announce the results of the vote of its annual …

Dynacor fait le point sur ses activités, notamment sur l'avancement de son expansion

Dynacor fait le point sur ses activités, notamment sur l'avancement de son expansion

MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor inc. (TSX : DNG) (« Dynacor » ou la « Société ») est heureuse de fournir une mise à jour sur ses activités et les progrès réalisés dans le cadre de son plan d'expansion en Afrique de l'Ouest et en …

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to …

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions